Pfizer’s Prevenar 13 garners European approval

Pfizer announced that the European Commission approved the use of Prevenar 13 (pneumococcal 13-valent conjugate vaccine) in children aged six weeks to five years to prevent invasive pneumococcal disease, as well as pneumonia and otitis media caused by 13 pneumococcal serotypes.

The company is also seeking US approval of the vaccine under the name Prevnar 13, with a decision from the FDA expected by December 30.

> The pharmaceutical industry and social media -- who leads, and who follows?
Pharma and Social Media: The Leaders and Followers - click here to find out more

To read more Top Story articles, click here.